Abstract
Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are part of a spectrum of thrombotic microangiopathies. In the last years enormous progress has been made in understanding the pathogenesis of these entities. The fact that complement dysregulation is considered central in the development of atypical hemolytic uremic syndrome has led to the introduction of Eculizumab, a monoclonal anti-C5 inhibitor, in its treatment. These new advances have improved the outcomes in patients with atypical hemolytic uremic syndrome. Many unsolved issues remains, the most pressing ones being identifying the optimal treatment schedules and the underlying cause of the disease in patients without detectable complement mutations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
